Amanda Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amanda Johnson has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Pulsipher
Division of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT
3 shared publications - Sung Won Choi
Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA
3 shared publications Alima Suleimenova
Michael Cuccione Childhood Cancer research program, British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada
2 shared publications- Alvina Salim
College of Design, University of Minnesota, Minneapolis, Minnesota, USA
2 shared publications - Andrew C. Harris
MSK Kids Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications Andrew Gilman
35Medical Monitoring Support Center, ICON Biotech, Center for Cell and Gene Therapy, Charlotte, NC
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-19
“I’ll Just Do It”: Designing for the Hidden Work of Collaborative Family Caregiving
- 13 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-19
Open Access“I’ll Just Do It”: Designing for the Hidden Work of Collaborative Family Caregiving
- Open Access
- 27 March 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3)
Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a life-threatening monogenic inborn error of immunity caused by pathogenic variants in the FOXP3 gene. In this report, we describe the clinical and immunologic consequences of a novel FOXP3 variant in an infant with refractory IPEX syndrome. Rapid whole-genome sequencing revealed a missense variant c.1050C>G (p.Ile350Met) in the forkhead domain of FOXP3. FOXP3 expression was abrogated in the regulatory T cell (Treg) subset but was maintained at low levels in activated effector T cells. The frequency of Treg-specific demethylated region (TSDR)–demethylated T cells was within normal range at birth, but it increased to pathologically high levels at 2 wk of age, prior to manifestation of disease symptoms. These results support the clinical relevance of the TSDR-demethylated cell percentage in evaluation of disease activity in IPEX. This case highlights a severe form of IPEX syndrome refractory to multiple immunosuppressive agents and the importance of early immunological studies to verify the clinical significance of novel genetic findings.
- 27 March 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3)
Open AccessRefractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a life-threatening monogenic inborn error of immunity caused by pathogenic variants in the FOXP3 gene. In this report, we describe the clinical and immunologic consequences of a novel FOXP3 variant in an infant with refractory IPEX syndrome. Rapid whole-genome sequencing revealed a missense variant c.1050C>G (p.Ile350Met) in the forkhead domain of FOXP3. FOXP3 expression was abrogated in the regulatory T cell (Treg) subset but was maintained at low levels in activated effector T cells. The frequency of Treg-specific demethylated region (TSDR)–demethylated T cells was within normal range at birth, but it increased to pathologically high levels at 2 wk of age, prior to manifestation of disease symptoms. These results support the clinical relevance of the TSDR-demethylated cell percentage in evaluation of disease activity in IPEX. This case highlights a severe form of IPEX syndrome refractory to multiple immunosuppressive agents and the importance of early immunological studies to verify the clinical significance of novel genetic findings.
- Open Access
- 19 February 2026
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 18, e81971
“Tough Things You’re Going to Have to Go Through”: Dyadic Interview Study Including the Perspectives and Needs of Patients and Their Caregivers Post-Hematopoietic Cell Transplant
Background: Patients undergoing hematopoietic cell transplant (HCT) and their caregivers are under a significant amount of stress throughout the HCT process with fear of disease recurrence, graft failure, and many other HCT-related complications. However, the needs and perspectives of patients undergoing HCT and their caregivers as dyadic units over the peri-HCT period are continuing to be studied and are an evolving field of research. Objective: To better understand patient and caregiver perspectives throughout the HCT course, patients undergoing HCT and their caregivers were able to opt-in to interviews at multiple time points post-HCT as part of a larger study, Roadmap 2.0 (an app intervention trial to support caregivers of patients undergoing HCT). Methods: Semistructured, dyadic (patient and caregiver) interviews took place around hospital discharge, day +30, +60, +90 and +120 post-HCT. Patient and caregiver discussions at each interview centered around a variety of topics including desired post-HCT information, coping, and additional resources for patients and their caregivers with the goal of gathering feedback to better inform future studies after Roadmap 2.0 and better understand the needs and perspectives of patients undergoing HCT and their caregivers. Interviews were transcribed and double-coded with inductive and deductive content analysis using the framework method to identify key findings. Results: A total of 10 patient-caregiver dyads participated, resulting in 48 dyadic interviews (1 patient died). Multiple findings emerged out of these rich discussions, including the progression from immediately post-discharge to when patients undergoing HCT and their caregivers were further out from HCT. The progression was as follows: “desire for data and tracking” to “need for specific restrictions and outline on forward progress,” to “need for additional directed information as progressing forward,” to “bigger picture and getting back to life,” and concluding with “reflection and fear.” Most patients and caregivers felt they were provided sufficient general anticipatory guidance throughout the HCT process but called for more specific expectations and guidance on a variety of issues. Many patients and caregivers used multiple coping strategies during HCT, with their coping strategies largely staying consistent over time. Additionally, the need for further acknowledgment and focus on the stress HCT places on caregivers was frequently discussed. Conclusions: Patients undergoing HCT and their caregivers were largely satisfied with the information and anticipatory guidance they were given but stressed a desire for more specific information throughout their HCT course. A variety of coping strategies are used by patients and their caregivers post-HCT, and these were consistently used over time. However, increased awareness and acknowledgment of the strain HCT places on caregivers are needed within the health care setting and in the general population. Future directions include continued incorporation of qualitative interviews with patients and caregivers as HCT-related interventions and apps.
- 19 February 2026
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 18, e81971
Open Access“Tough Things You’re Going to Have to Go Through”: Dyadic Interview Study Including the Perspectives and Needs of Patients and Their Caregivers Post-Hematopoietic Cell Transplant
Background: Patients undergoing hematopoietic cell transplant (HCT) and their caregivers are under a significant amount of stress throughout the HCT process with fear of disease recurrence, graft failure, and many other HCT-related complications. However, the needs and perspectives of patients undergoing HCT and their caregivers as dyadic units over the peri-HCT period are continuing to be studied and are an evolving field of research. Objective: To better understand patient and caregiver perspectives throughout the HCT course, patients undergoing HCT and their caregivers were able to opt-in to interviews at multiple time points post-HCT as part of a larger study, Roadmap 2.0 (an app intervention trial to support caregivers of patients undergoing HCT). Methods: Semistructured, dyadic (patient and caregiver) interviews took place around hospital discharge, day +30, +60, +90 and +120 post-HCT. Patient and caregiver discussions at each interview centered around a variety of topics including desired post-HCT information, coping, and additional resources for patients and their caregivers with the goal of gathering feedback to better inform future studies after Roadmap 2.0 and better understand the needs and perspectives of patients undergoing HCT and their caregivers. Interviews were transcribed and double-coded with inductive and deductive content analysis using the framework method to identify key findings. Results: A total of 10 patient-caregiver dyads participated, resulting in 48 dyadic interviews (1 patient died). Multiple findings emerged out of these rich discussions, including the progression from immediately post-discharge to when patients undergoing HCT and their caregivers were further out from HCT. The progression was as follows: “desire for data and tracking” to “need for specific restrictions and outline on forward progress,” to “need for additional directed information as progressing forward,” to “bigger picture and getting back to life,” and concluding with “reflection and fear.” Most patients and caregivers felt they were provided sufficient general anticipatory guidance throughout the HCT process but called for more specific expectations and guidance on a variety of issues. Many patients and caregivers used multiple coping strategies during HCT, with their coping strategies largely staying consistent over time. Additionally, the need for further acknowledgment and focus on the stress HCT places on caregivers was frequently discussed. Conclusions: Patients undergoing HCT and their caregivers were largely satisfied with the information and anticipatory guidance they were given but stressed a desire for more specific information throughout their HCT course. A variety of coping strategies are used by patients and their caregivers post-HCT, and these were consistently used over time. However, increased awareness and acknowledgment of the strain HCT places on caregivers are needed within the health care setting and in the general population. Future directions include continued incorporation of qualitative interviews with patients and caregivers as HCT-related interventions and apps.
- Top Cited PapersOpen Access
- 15 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (3) , 241-253
Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation
Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE1.0 and 2.0 studies (51 patients with cGVHD and 158 with non-cGVHD). We found 3 distinct cGVHD subtypes: cGVHD-1 was characterized by an effector memory T-cell, cytotoxic natural killer cell, and early precursor B-cell predominant pattern; cGVHD-2 was phosphatidylcholine, cytokine, and plasma cell predominant; and cGVHD-3 had more naïve CD4+ T cells and naïve regulatory T cells, had later onset, and was the only subtype with measurable T-cell receptor excision circles. We partially replicated these subtypes using metabolomic data from a separate pediatric cohort of the Children’s Oncology Group trial ASCT0031 (33 patients with cGVHD and 39 with non-cGVHD). Furthermore, cGVHD-1 was associated with serotherapy (predominantly antithymocyte globulin) exposure, and cGVHD-3 was associated with receiving peripheral blood stem cells from donors, total body irradiation, and no previous acute GVHD. cGVHD-2 was associated with liver involvement and cGVHD-2 and -3 with de novo cGVHD. Overall, none of the subtypes were closely associated with organ involvement. Contrasting each subtype against patients with non-cGVHD, the 3 subtypes shared common markers, all of which were used in our previous cGVHD diagnostic classifier. These findings suggest the presence of distinct biological subtypes of cGVHD that may help guide therapeutic strategies.
- 15 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (3) , 241-253
Top Cited PapersOpen AccessDistinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation
Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE1.0 and 2.0 studies (51 patients with cGVHD and 158 with non-cGVHD). We found 3 distinct cGVHD subtypes: cGVHD-1 was characterized by an effector memory T-cell, cytotoxic natural killer cell, and early precursor B-cell predominant pattern; cGVHD-2 was phosphatidylcholine, cytokine, and plasma cell predominant; and cGVHD-3 had more naïve CD4+ T cells and naïve regulatory T cells, had later onset, and was the only subtype with measurable T-cell receptor excision circles. We partially replicated these subtypes using metabolomic data from a separate pediatric cohort of the Children’s Oncology Group trial ASCT0031 (33 patients with cGVHD and 39 with non-cGVHD). Furthermore, cGVHD-1 was associated with serotherapy (predominantly antithymocyte globulin) exposure, and cGVHD-3 was associated with receiving peripheral blood stem cells from donors, total body irradiation, and no previous acute GVHD. cGVHD-2 was associated with liver involvement and cGVHD-2 and -3 with de novo cGVHD. Overall, none of the subtypes were closely associated with organ involvement. Contrasting each subtype against patients with non-cGVHD, the 3 subtypes shared common markers, all of which were used in our previous cGVHD diagnostic classifier. These findings suggest the presence of distinct biological subtypes of cGVHD that may help guide therapeutic strategies.
- Open Access
- 1 October 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 84.e1-84.e16
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort
- 1 October 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 84.e1-84.e16
Open AccessIdentification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort
- Open Access
- 2 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
“Tough things you’re going to have to go through”: A dyadic interview study of patients and their caregivers post-hematopoietic cell transplant (HCT) (Preprint)
BACKGROUND Patients undergoing hematopoietic cell transplant (HCT) and their caregivers are under a significant amount of stress throughout the HCT process with fear of disease recurrence, graft failure, and many other HCT-related complications. However, the experiences and perspectives of HCT patients and their caregivers as dyadic units have not been well-published to date. OBJECTIVE To better understand patient and caregiver perspectives throughout the HCT course, patients undergoing HCT and their caregivers were able to opt-in to interviews at multiple time points post-HCT as part of a larger study, Roadmap 2.0 (an app intervention trial to support HCT caregivers). METHODS Semi-structured, dyadic (patient and caregiver) interviews took place around hospital discharge, day +30, +60, +90 and +120 post-HCT. Patient and caregiver discussions at each interview centered around a variety of topics including desired post-HCT information, coping, and additional resources for patients and their caregivers with the goal of gathering feedback to better inform future studies after Roadmap 2.0. Interviews were transcribed and double coded with inductive and deductive content analysis utilizing the Framework Method to identify key findings. RESULTS Multiple findings emerged out of these rich discussions including the progression from immediately post-discharge to when HCT patients and their caregivers were further out from HCT. The progression was as follows: “Desire for data and tracking” to “Need for specific restrictions and outline on forward progress,” to “Need for additional directed information as progressing forward,” to “Bigger picture and getting back to life,” and concluding with “Reflection and fear.” Most patients and caregivers felt they were provided sufficient general anticipatory guidance throughout the HCT process but called for more specific expectations and guidance on a variety of issues. Many patients and caregivers employed multiple coping strategies during HCT with their coping strategies largely staying consistent over time. The most common coping strategy used by patients and caregivers was “Coping through social networks.” Additionally, the need for further acknowledgement and focus on the stress HCT places on caregivers was frequently discussed. Feedback on the Roadmap 2.0 app and app design for this population were also gathered. CONCLUSIONS Patients undergoing HCT and their caregivers were largely satisfied with the information and anticipatory guidance they were given but stressed a desire for more specific information throughout their HCT course. A variety of coping strategies are utilized by patients and their caregivers post-HCT and these were consistently utilized over time. However, increased awareness and acknowledgement of the strain HCT places on caregivers is needed within the healthcare setting and in the general population. Future directions include continued incorporation of qualitative interviews with patients and caregivers as HCT-related interventions and apps are designed, beta tested and used in larger studies. CLINICALTRIAL Health Information Technology System (“Roadmap 2.0”) in the Context of Hematopoietic Cell Transplantation (ClinicalTrials.gov NCT04094844, https://clinicaltrials.gov/study/NCT04094844).
- 2 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open Access“Tough things you’re going to have to go through”: A dyadic interview study of patients and their caregivers post-hematopoietic cell transplant (HCT) (Preprint)
BACKGROUND Patients undergoing hematopoietic cell transplant (HCT) and their caregivers are under a significant amount of stress throughout the HCT process with fear of disease recurrence, graft failure, and many other HCT-related complications. However, the experiences and perspectives of HCT patients and their caregivers as dyadic units have not been well-published to date. OBJECTIVE To better understand patient and caregiver perspectives throughout the HCT course, patients undergoing HCT and their caregivers were able to opt-in to interviews at multiple time points post-HCT as part of a larger study, Roadmap 2.0 (an app intervention trial to support HCT caregivers). METHODS Semi-structured, dyadic (patient and caregiver) interviews took place around hospital discharge, day +30, +60, +90 and +120 post-HCT. Patient and caregiver discussions at each interview centered around a variety of topics including desired post-HCT information, coping, and additional resources for patients and their caregivers with the goal of gathering feedback to better inform future studies after Roadmap 2.0. Interviews were transcribed and double coded with inductive and deductive content analysis utilizing the Framework Method to identify key findings. RESULTS Multiple findings emerged out of these rich discussions including the progression from immediately post-discharge to when HCT patients and their caregivers were further out from HCT. The progression was as follows: “Desire for data and tracking” to “Need for specific restrictions and outline on forward progress,” to “Need for additional directed information as progressing forward,” to “Bigger picture and getting back to life,” and concluding with “Reflection and fear.” Most patients and caregivers felt they were provided sufficient general anticipatory guidance throughout the HCT process but called for more specific expectations and guidance on a variety of issues. Many patients and caregivers employed multiple coping strategies during HCT with their coping strategies largely staying consistent over time. The most common coping strategy used by patients and caregivers was “Coping through social networks.” Additionally, the need for further acknowledgement and focus on the stress HCT places on caregivers was frequently discussed. Feedback on the Roadmap 2.0 app and app design for this population were also gathered. CONCLUSIONS Patients undergoing HCT and their caregivers were largely satisfied with the information and anticipatory guidance they were given but stressed a desire for more specific information throughout their HCT course. A variety of coping strategies are utilized by patients and their caregivers post-HCT and these were consistently utilized over time. However, increased awareness and acknowledgement of the strain HCT places on caregivers is needed within the healthcare setting and in the general population. Future directions include continued incorporation of qualitative interviews with patients and caregivers as HCT-related interventions and apps are designed, beta tested and used in larger studies. CLINICALTRIAL Health Information Technology System (“Roadmap 2.0”) in the Context of Hematopoietic Cell Transplantation (ClinicalTrials.gov NCT04094844, https://clinicaltrials.gov/study/NCT04094844).
- Open Access
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-8
"Count on Me": Enabling Collaboration Through Active Support for Primary Family Caregivers in Chronic Illness Care
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-8
Open Access"Count on Me": Enabling Collaboration Through Active Support for Primary Family Caregivers in Chronic Illness Care
- 1 August 2022
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 25 (8) , 1313
Living in the Dying
Journal of Palliative Medicine
- 1 August 2022
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 25 (8) , 1313
Living in the Dying
Journal of Palliative Medicine
- Open Access
- 2 December 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (12) , e13671
Use of Mobile Health Apps and Wearable Technology to Assess Changes and Predict Pain During Treatment of Acute Pain in Sickle Cell Disease: Feasibility Study
Background: Sickle cell disease (SCD) is an inherited red blood cell disorder affecting millions worldwide, and it results in many potential medical complications throughout the life course. The hallmark of SCD is pain. Many patients experience daily chronic pain as well as intermittent, unpredictable acute vaso-occlusive painful episodes called pain crises. These pain crises often require acute medical care through the day hospital or emergency department. Following presentation, a number of these patients are subsequently admitted with continued efforts of treatment focused on palliative pain control and hydration for management. Mitigating pain crises is challenging for both the patients and their providers, given the perceived unpredictability and subjective nature of pain. Objective: The objective of this study was to show the feasibility of using objective, physiologic measurements obtained from a wearable device during an acute pain crisis to predict patient-reported pain scores (in an app and to nursing staff) using machine learning techniques. Methods: For this feasibility study, we enrolled 27 adult patients presenting to the day hospital with acute pain. At the beginning of pain treatment, each participant was given a wearable device (Microsoft Band 2) that collected physiologic measurements. Pain scores from our mobile app, Technology Resources to Understand Pain Assessment in Patients with Pain, and those obtained by nursing staff were both used with wearable signals to complete time stamp matching and feature extraction and selection. Following this, we constructed regression and classification machine learning algorithms to build between-subject pain prediction models. Results: Patients were monitored for an average of 3.79 (SD 2.23) hours, with an average of 5826 (SD 2667) objective data values per patient. As expected, we found that pain scores and heart rate decreased for most patients during the course of their stay. Using the wearable sensor data and pain scores, we were able to create a regression model to predict subjective pain scores with a root mean square error of 1.430 and correlation between observations and predictions of 0.706. Furthermore, we verified the hypothesis that the regression model outperformed the classification model by comparing the performances of the support vector machines (SVM) and the SVM for regression. Conclusions: The Microsoft Band 2 allowed easy collection of objective, physiologic markers during an acute pain crisis in adults with SCD. Features can be extracted from these data signals and matched with pain scores. Machine learning models can then use these features to feasibly predict patient pain scores.
- 2 December 2019
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 7 (12) , e13671
Open AccessUse of Mobile Health Apps and Wearable Technology to Assess Changes and Predict Pain During Treatment of Acute Pain in Sickle Cell Disease: Feasibility Study
Background: Sickle cell disease (SCD) is an inherited red blood cell disorder affecting millions worldwide, and it results in many potential medical complications throughout the life course. The hallmark of SCD is pain. Many patients experience daily chronic pain as well as intermittent, unpredictable acute vaso-occlusive painful episodes called pain crises. These pain crises often require acute medical care through the day hospital or emergency department. Following presentation, a number of these patients are subsequently admitted with continued efforts of treatment focused on palliative pain control and hydration for management. Mitigating pain crises is challenging for both the patients and their providers, given the perceived unpredictability and subjective nature of pain. Objective: The objective of this study was to show the feasibility of using objective, physiologic measurements obtained from a wearable device during an acute pain crisis to predict patient-reported pain scores (in an app and to nursing staff) using machine learning techniques. Methods: For this feasibility study, we enrolled 27 adult patients presenting to the day hospital with acute pain. At the beginning of pain treatment, each participant was given a wearable device (Microsoft Band 2) that collected physiologic measurements. Pain scores from our mobile app, Technology Resources to Understand Pain Assessment in Patients with Pain, and those obtained by nursing staff were both used with wearable signals to complete time stamp matching and feature extraction and selection. Following this, we constructed regression and classification machine learning algorithms to build between-subject pain prediction models. Results: Patients were monitored for an average of 3.79 (SD 2.23) hours, with an average of 5826 (SD 2667) objective data values per patient. As expected, we found that pain scores and heart rate decreased for most patients during the course of their stay. Using the wearable sensor data and pain scores, we were able to create a regression model to predict subjective pain scores with a root mean square error of 1.430 and correlation between observations and predictions of 0.706. Furthermore, we verified the hypothesis that the regression model outperformed the classification model by comparing the performances of the support vector machines (SVM) and the SVM for regression. Conclusions: The Microsoft Band 2 allowed easy collection of objective, physiologic markers during an acute pain crisis in adults with SCD. Features can be extracted from these data signals and matched with pain scores. Machine learning models can then use these features to feasibly predict patient pain scores.
- 1 June 2005
- Published by Elsevier in Personality and Individual Differences
- Vol. 38 (8) , 1847-1853
Me, myself, and lie: The role of self-awareness in deception
- 1 June 2005
- Published by Elsevier in Personality and Individual Differences
- Vol. 38 (8) , 1847-1853
Me, myself, and lie: The role of self-awareness in deception